Abstract: Objective To analyze the effect of budesonide on the level of chemokin-like factor-1 (CKLF-1) and immune function in children with acute asthma induced by infection. Methods The clinical data of 100 cases of acute attack of infection-induced asthma treated in our hospital from March 2015 to May 2018 were selected for analysis, and were divided into two. The control group received routine treatment. The observation group was given with budesonide on the basis of the control group, and the clinical efficacy of the two groups of patients after treatment was analyzed. Results The scores of daytime and nighttime symptoms in the observation group were lower than those in the control group and the number of acute attacks was lower than those in the control group within 6 weeks and 12 weeks, and the difference was statistically significant (t=23.276,20.732,53.137,48.590,12.514,P<0.001).There were no statistically significant difference in levels of inflammatory cytokines, T-lymphocyte subsets and pulmonary function levels between the two groups before treatment (t=0.097,0.020,0.251,1.299,1.301,0.272,0.151,0.208,0.100,0.294,P＞0.05). After treatment, the levels of interferon (IFN-γ), T lymphocyte subsets, forced expiratory volume in 1 second (FEV1), vital capacity (VC), FEV1 percentage of expected value (FEV1 %), and the levels of forced vital capacity (FVC) were higher in the observation group observation group than the control group, chemotaxis sample factor 1 (CKLF-1), tumor necrosis factor alpha (TNF-α), interleukin 4 (IL-4) level were lower than those in the control group (t=3.940,7.707,7.740,3.909,5.289,17.220,3.885,6.932,5.028,19.941,17.665,P＜0.01). Conclusion The treatment of budesonide in children with acute attack of infection-induced asthma can reduce the IL-4 level of CKLF-1TNF-α, increase the level IFN-γ in patients, and effectively improve the clinical symptoms, lung function and immune function of children.

Key words: budesonide, asthma, lung function, inflammatory cytokines

摘要： 目的 分析布地奈德对感染诱发哮喘急性发作患儿趋化素样因子-1(CKLF-1)水平及免疫功能的影响,为临床防治提供理论依据。方法 选取焦作市第二人民医院于2015年3月-2018年5月收治的100例感染诱发哮喘急性发作患儿的临床资料进行分析,分为两组。对照组采用常规治疗,观察组在对照组的基础上给予布地奈德治疗,分析两组患者治疗后的临床疗效。结果 观察组患儿6周内、12周内日间症状及夜间症状积分低于对照组,急性发作次数少于对照组,差异有统计学意义(t=23.276、20.732、53.137、48.590、12.514,P<0.001)。两组患儿治疗前炎症因子、T淋巴细胞亚群、肺功能水平比较,差异无统计学意义(t=0.097、0.020、0.251、1.299、1.301、0.272、0.151、0.208、0.100、0.294,P＞0.05)。观察组患儿治疗后干扰素-γ(IFN-γ)、T淋巴细胞亚群、第1秒用力呼气容积(FEV₁)、肺活量(VC)、FEV₁占预计值百分比(FEV₁%)、用力肺活量(FVC)水平高于对照组,趋化素样因子-1(CKLF-1)、肿瘤坏死因子-α(TNF-α)、白介素-4(IL-4)水平低于对照组(t=3.940、7.707、7.740、3.909、5.289、17.220、3.885、6.932、5.028、19.941、17.665,P＜0.01)。结论 布地奈德治疗感染诱发哮喘急性发作患儿,可降低CKLF-1、TNF-α、IL-4水平,增高IFN-γ水平,有效改善患儿临床症状、肺功能和免疫功能。

关键词: 布地奈德, 哮喘, 肺功能, 炎症因子